Document is current

Any future updates will be listed below

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

Crossref DOI link: https://doi.org/10.1038/s41467-017-02205-9

Published Online: 2018-01-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark